Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

Sandfire Resources share price jumps 3% after Australia Day break; what ASX:SFR investors watch next

Sandfire Resources share price jumps 3% after Australia Day break; what ASX:SFR investors watch next

Sandfire Resources rose 3.4% to A$19.71 Tuesday, nearing its 52-week high as materials stocks led the ASX 200 up 0.9% after the holiday break. The company maintained its FY26 copper output forecast and reported $13 million net cash at year-end. Key events ahead include a Feb. 6 shareholder vote on its Kalkaroo acquisition and half-year results due Feb. 19.
CBA share price rises, but Commonwealth Bank loses ASX top spot to BHP as rate bets build

CBA share price rises, but Commonwealth Bank loses ASX top spot to BHP as rate bets build

Commonwealth Bank of Australia closed up 0.5% at A$150.22, but lost its top spot to BHP after a surge in mining stocks. The ASX 200 rose 0.9% to its highest since October. Traders await Wednesday’s inflation data and the Reserve Bank of Australia’s rate decision on Feb. 3. CBA will report half-year results and announce an interim dividend on Feb. 11.
27 January 2026
Central Puerto (CEPU) stock rises in New York — what investors are watching ahead of the Fed

Central Puerto (CEPU) stock rises in New York — what investors are watching ahead of the Fed

Central Puerto’s U.S.-listed shares rose 2.8% to $16.91 Monday, after swinging between $16.23 and $17.95 with 731,000 shares traded. Argentina-linked assets gained, with the Global X MSCI Argentina ETF up 1.5%. Investors tracked Federal Reserve signals and recent Central Puerto filings, including a $300 million IFC financing and a 30-year hydroelectric concession.
Almonty Industries stock jumps in New York as tungsten supply anxiety keeps building

Almonty Industries stock jumps in New York as tungsten supply anxiety keeps building

Almonty Industries shares rose about 6% to $11.79 Monday after an SEC filing revealed a 2026 tungsten delivery contract tied to its Panasqueira mine in Portugal. Trading volume topped 8.8 million. The move comes as U.S. defense rules and Chinese export limits push investors to seek non-Chinese tungsten sources. Most contract pricing and volumes remain undisclosed.
Cloudflare stock jumps on viral ‘Clawdbot’ AI-agent buzz as Wall Street eyes Feb. 10 earnings

Cloudflare stock jumps on viral ‘Clawdbot’ AI-agent buzz as Wall Street eyes Feb. 10 earnings

Cloudflare shares surged 11.5% to $193.30 Monday, outpacing sector rivals after social media buzz around “Clawdbot,” an open-source AI agent built on Anthropic’s Claude. Wolfe Research linked the rally to expectations that Cloudflare’s network could benefit if AI-driven traffic rises. Investors await Cloudflare’s Feb. 10 earnings and the Federal Reserve’s policy decision this week. Akamai, Fastly, and Zscaler also posted gains.
1 93 94 95 96 97 535

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
Go toTop